Risultati per: Linee guida ESC/ERS 2022 per la diagnosi e il trattamento dell'ipertensione polmonare

This study assesses differences in breastfeeding initiation trends between Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) participants and WIC-eligible nonparticipants before, during, and after the 2022 infant formula disruption.

Curata da Arrigoni, Malafarina e Sani e promossa dalla Cpo

Rapporto Visentini, confermata la difficile ripresa post pandemia

Ridurranno del 70% gli esami inutili

Miglioramento della sopravvivenza a 5 anni se il tumore è in fase precoce

This study analyzes trends in US mortality attributed to both diabetic ketoacidosis and hyperosmolar hyperglycemic state from 1999-2022.

Stroke, Volume 55, Issue Suppl_1, Page A67-A67, February 1, 2024. Background:People with acute stroke are at high risk of dementia. Population-wide data on the risk and time-course of dementia after stroke are lacking.Methods:We conducted a population-wide analysis of over 15 million people in Ontario, Canada between 2002-2022. Using linked administrative databases, we compared all 90-day survivors of first acute ischemic stroke or intracerebral hemorrhage (ICH) to controls in the general population and with acute myocardial infarction (AMI) by matching 1:1 on age, sex, rural residence, neighborhood marginalization, and vascular comorbidities, and excluded people with prior dementia. We evaluated the rate of dementia per 100 person-years using a validated definition which included hospitalization, physician claims, and medications, and calculated cause-specific hazard ratios overall and across follow-up time.Results:We identified 180,940 people with acute stroke, of which 33,765 (18.7%) developed dementia over mean follow-up of 5.5 years (max 20y). The rate of dementia per 100 person-years was highest after acute stroke compared to the general population (3.40 vs. 1.88) and compared to AMI (3.23 vs. 1.81). The overall risk of dementia was higher in those with acute stroke compared to the general population (HR 1.79, 95% CI 1.76-1.82; Figure 1A), and particularly after ICH (HR 2.43, 2.31-2.57). The results were similar when compared to AMI (HR 1.77, 1.74-1.80; Figure 1C). There was an almost 3-fold elevation of dementia risk in the first year after stroke, decreasing to 1.5-fold by 5 years and remaining elevated even 20 years after (Figure 1B/1D).Conclusion:In this large, population-wide study almost one fifth of people developed dementia after stroke, with an 80% higher risk of developing dementia compared to matched controls. The risk was highest early after stroke but remained elevated 20 years after, raising the urgency of developing interventions for dementia prevention in acute and chronic survivors of stroke.

Stroke, Volume 55, Issue Suppl_1, Page AWP288-AWP288, February 1, 2024. Background:Cerebrovascular diseases (CVD) represent a Global Health concern, being the first cause of disability worldwide and second cause of mortality (first in Brazil). Despite that, detailed data from Brazil was scarce and this study found alarming results.Aims:The study aims to analyze incidence, mortality, treatment, procedures and costs related to the three most common cerebrovascular diseases: Subarachnoid Hemorrhage (SAH), Intracerebral Hemorrhage (ICH) and Ischemic Stroke in Brazil.Methods:This is an epidemiological study. Data was obtained through DataSUS, a public database. For the search, we utilized the CID-10 notification system from I60 until I64, including admissions, deaths, treatments and costs related to each CID-10.Results:Between 2017 and 2022, 1,283,435 CVD cases were notified (SAH=4,7%; ICH= 8.8%; and ischemic stroke=86.5%). 52.4% were Male and 47.6% were Female. Mortality percentages were: SAH=20.2%, ICH=25.3%, Ischemic Stroke=15.3%. Rates of Thrombolysis were alarming, but with an increasing tendency: 22969 were performed, from 1.6% in 2017 to 2.3% in 2022 of all ischemic strokes. 8290 aneurysms embolizations were performed (13.5% of all SAH cases). 4.9% of SAH cases were treated with neurosurgical clipping, demonstrating a decrease tendency after 2020, as well other procedures, such as Craniectomy and Angioplastia. Yearly costs related to these diseases increased steeply, from R$ 360,710,749.92 in 2017 to R$ 537,511,793.62 in 2022 (around US$107,502,358.00).Conclusions:This study has found increasing incidence and costs associated with low rates of thrombolysis and procedures in Brazil The results can direct Public Health policies in developing countries, and similar research in other low- and middle-income-countries are encouraged.

Stroke, Volume 55, Issue Suppl_1, Page AWP100-AWP100, February 1, 2024. Introduction:IV thrombolysis is a proven treatment for acute ischemic stroke (AIS), but it is still underutilized in real-world clinical practice. Using a nationwide multicenter stroke registry, we aimed to determine whether there are significant trends in the rate of IV thrombolysis in different patient populations.Methods:This study assessed patients with AIS or transient ischemic attack (TIA) registered prospectively in the Clinical Research Center for Stroke-Korea (CRCS-K) registry between 2013 and 2022. Trends in IV thrombolysis rate were respectively analyzed for all patients (cohort 1), patients who arrived at the hospital within 4.5 hours of onset (cohort 2), and patients potentially eligible for IV thrombolysis (cohort 3), using joinpoint regression analysis. Trends in IV thrombolysis rates in cohorts 1-3 were further investigated using generalized linear mixed-effects models adjusted for patient characteristics and accounting for hospital heterogeneity.Results:A total of 76535 patients were included in the analysis. The mean age of the patients increased from 67.3 to 69.8 years, and the median time from onset to hospital arrival increased over the 10-year period. During the study period, proportion of patients arriving at the hospital within 4.5 hours of onset and the proportion of patients potentially eligible for IV thrombolysis decreased, especially after 2016. IV thrombolysis rates significantly declined over the 10-year period in cohorts 1-3, with a pronounced decrease in the treatment rate in potentially IV thrombolysis eligible patients from 2013 to 2016 (average annual percent change [95% CI] -4.55% [-5.66% to -3.46%] in cohort 1; -2.63% [-3.95% to -1.34%] in cohort 2; -1.33% [-2.06% to -0.49%] in cohort 3). In the multivariable model, patients who arrived in 2022 were less likely to receive IV thrombolysis compared to patients who arrived in 2013 (adjusted odds ratio [95% CI], 0.83 [0.75 – 0.93]).Conclusions:Utilization of IV thrombolysis has declined over the decade in Korea, even accounting for the decline in the number of patients who are candidates for the treatment. Urgent interventions to increase IV thrombolysis rates are needed to improve acute stroke care.

Studio ISS, IRCCS Milano, ‘nel 2020 23,7 milioni dai 16,8 del 2010’